TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behcet's syndrome refractory to the conventional treatment modalities: a case series and review of the literature

Basit Öğe Kaydı
dc.authoridHatemi, Ali Ibrahim/0000-0002-8385-9253
dc.authoridHatemi, Gulen/0000-0002-1952-1135
dc.authoriderzin, yusuf/0000-0002-9460-1469
dc.authorwosidHatemi, Gulen/AFM-7014-2022
dc.authorwosidHatemi, Ali Ibrahim/AAA-3618-2020
dc.authorwosidHatemi, Gulen/AAC-9647-2021
dc.contributor.authorHatemi, I.
dc.contributor.authorHatemi, G.
dc.contributor.authorPamuk, O. N.
dc.contributor.authorErzin, Y.
dc.contributor.authorCelik, A. F.
dc.date.accessioned2024-06-12T10:54:20Z
dc.date.available2024-06-12T10:54:20Z
dc.date.issued2015
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjective. Gastrointestinal involvement of Behcet's syndrome is usually treated with glucocorticoids, 5-aminosalicylic acid compounds and azathioprine. However, some patients are refractory to these conventional therapy modalities. In this paper we report our experience on 13 patients with gastrointestinal involvement of Behcet's syndrome who were refractory to the conventional therapy and who were treated with TNFalpha antagonists and/or thalidomide. Methods. We reviewed the charts of our Behcet's syndrome patients with gastrointestinal involvement and identified those who were treated with TNF alpha antagonists and/or thalidomide. Demographic features, previous and concomitant drugs, previous surgery, time to remission and duration of remission were tabulated. We also performed a systematic review of publications on gastrointestinal involvement of Behcet's syndrome patients treated with TNFalpha antagonists and/or thalidomide. Results. Among our 64 patients with gastrointestinal involvement of Behcet's syndrome, we identified 13 (20%) (7 women, 6 men, mean age 27.4 +/- 9.4) who had been treated with TNF-alpha antagonists and/or thalidomide. Their previous medications were glucocorticoids (13113), azathioprine (13113), 5-aminosalicylic acid derivatives (3113) and budesonide (1113). Clinical and endoscopic remission was obtained in 10 patients. One patient died with sepsis. The systematic literature search revealed 91 cases who had used TNFalpha antagonists and 15 who had used thalidomide. Among the patients who had received TNF-alpha antagonists, clinical remission was obtained in 47191 patients (51%), while endoscopic remission was observed in 21/46(45%) who had a control colonoscopy. Conclusion. One fifth of our Behcet's syndrome patients with gastrointestinal involvement were refractory to conventional treatment modalities. Remission was obtained with TNF-alpha antagonists and/or thalidomide in about 75 % of the cases.en_US
dc.identifier.endpageS137en_US
dc.identifier.issn0392-856X
dc.identifier.issn1593-098X
dc.identifier.issue6en_US
dc.identifier.pmid26486925en_US
dc.identifier.startpageS129en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19007
dc.identifier.volume33en_US
dc.identifier.wosWOS:000365834600021en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherClinical & Exper Rheumatologyen_US
dc.relation.ispartofClinical And Experimental Rheumatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBehcet's Diseaseen_US
dc.subjectBehcet's Syndromeen_US
dc.subjectManagementen_US
dc.subjectIntestinal Involvementen_US
dc.subjectInflammatory Bowel Diseaseen_US
dc.subjectInfliximaben_US
dc.subjectEtanercepten_US
dc.subjectAdalimumaben_US
dc.subjectThalidomideen_US
dc.subjectNecrosis-Factor-Alphaen_US
dc.subjectDagger-Ets Diseaseen_US
dc.subjectMonoclonal-Antibody Therapyen_US
dc.subjectRandomized Clinical-Trialen_US
dc.subjectMyelodysplastic Syndromeen_US
dc.subjectIntestinal Involvementen_US
dc.subjectCombination Therapyen_US
dc.subjectCrohns-Diseaseen_US
dc.subjectInfliximaben_US
dc.subjectRemissionen_US
dc.titleTNF-alpha antagonists and thalidomide for the management of gastrointestinal Behcet's syndrome refractory to the conventional treatment modalities: a case series and review of the literatureen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu